Identification of repurposable cytoprotective drugs in Vanishing White Matter Disease patient-derived cells
Preprint
- 5 October 2020
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Vanishing white matter disease (VWMD) is a rare leukodystrophy caused by mutations of the guanine exchange factor eIF2B. VWMD typically presents with juvenile onset, and there are few treatments for the disease. Recent progress in the field has established mitochondrial dysfunction and endoplasmic reticulum (ER) stress to be strongly implicated in observed glial cell pathology. Drug repurposing offers a rapid approach toward translation of therapeutics using already-licensed drugs. Objective The aim of this study was to use fibroblasts and induced pluripotent stem cell (iPSC)-derived astrocytes from patients bearing the EIF2B5R113H/A403V or EIF2B2G200V/E213G VWMD mutations to identify potentially repurposable FDA-approved drugs based on in vitro assays. Methods Cell viability in the presence or absence of stress was assessed by resazurin reduction activity and assays for mitochondrial membrane potential, and oxidative stress. Integrated stress response markers, including eIF2α phosphorylation, GADD34 and CHOP were quantified by fluorescent western blot. Results Dysregulated GADD34 and CHOP were identified in patient fibroblasts and iPSC-derived astrocytes under induced stress conditions. A drug screen from a 2,400 FDA-approved drug library with EIF2B5R113H/A403V VWMD patient fibroblasts identified 113 anti-inflammatory drugs as a major class of hits with cytoprotective effects. A panel of potential candidate drugs, including berberine, deflazacort, ursodiol, zileuton, guanabenz and Anavex 2-73, and preclinical ISRIB, increased cell survival of EIF2B5R113H/A403V or EIF2B2G200V/E213G VWMD astrocytes, and were further investigated for their effect on the integrated stress response and mitochondrial stress. Ursodiol demonstrated capacity to ameliorate oxidative stress and loss of mitochondrial membrane potential in VWMD patient iPSC-derived astrocytes in the presence or absence of stress conditions. Conclusion Patient-derived cells can be used to identify cellular phenotypes and for large-scale drug screening. Anti-inflammatory compounds, such as berberine, deflazacort, ursodiol and zileuton are potentially repurposable drug candidates for VWMD that should be further investigated for translation in vivo.Keywords
All Related Versions
This publication has 44 references indexed in Scilit:
- Astrocyte Subtype Vulnerability in Stem Cell Models of Vanishing White MatterAnnals of Neurology, 2019
- Vanishing white matter: deregulated integrated stress response as therapy targetAnnals of Clinical and Translational Neurology, 2019
- eIF2B Mutations Cause Mitochondrial Malfunction in OligodendrocytesNeuroMolecular Medicine, 2019
- Natural History of Vanishing White MatterAnnals of Neurology, 2018
- Edaravone: A new drug approved for ALSCell, 2017
- Pharmacological advances for treatment in Duchenne muscular dystrophyCurrent Opinion in Pharmacology, 2017
- Proteasome inhibitor MG132-induced apoptosis via ER stress-mediated apoptotic pathway and its potentiation by protein tyrosine kinase p56lck in human Jurkat T cellsBiochemical Pharmacology, 2011
- Zileuton Reduces Inflammatory Reaction and Brain Damage Following Permanent Cerebral Ischemia in RatsInflammation, 2010
- Bile acids in treatment of ocular diseaseJournal of Ocular Biology, Diseases, and Informatics, 2009
- Nitric oxide‐induced apoptosis in cultured rat astrocytes: Protection by edaravone, a radical scavengerGlia, 2007